ArimaDex Maker Pulls Supplement From The Market

By ACSH Staff — Sep 21, 2010
Following an FDA investigation which found trace amounts of a contaminant — an aromatase inhibitor — in the “muscle building” supplement ArimaDex, the manufacturer Genetic Edge Technology voluntarily pulled the supplement off the market. Aromatase inhibitors are a class of drugs that block the synthesis of estrogen, which have been used in the treatment of breast and ovarian cancer in postmenopausal women.

Following an FDA investigation which found trace amounts of a contaminant — an aromatase inhibitor — in the “muscle building” supplement ArimaDex, the manufacturer Genetic Edge Technology voluntarily pulled the supplement off the market. Aromatase inhibitors are a class of drugs that block the synthesis of estrogen, which have been used in the treatment of breast and ovarian cancer in postmenopausal women.

Flu Vaccine May Reduce Heart Attack Risk

By ACSH Staff — Sep 21, 2010
In addition to providing immunity against the flu virus, it seems the seasonal flu vaccine may have the added benefit of reducing the risk of a first-time heart attack in middle-aged and older adults in the year subsequent to inoculation.

In addition to providing immunity against the flu virus, it seems the seasonal flu vaccine may have the added benefit of reducing the risk of a first-time heart attack in middle-aged and older adults in the year subsequent to inoculation.

Patients Skip Follow-Up Tests For Colon Cancer

By ACSH Staff — Sep 21, 2010
Patients are neglecting follow-up fecal blood tests to screen for colon and rectal cancer within the recommended two years of their initial test, researchers of a new study published in the Annals of Family Medicine say. In fact, of the 11,110 recruited study subjects between the ages of 52 and 78 who underwent a fecal occult blood test, 46.8 percent failed to have either a repeat test or any other form of follow-up colorectal cancer screening.

Patients are neglecting follow-up fecal blood tests to screen for colon and rectal cancer within the recommended two years of their initial test, researchers of a new study published in the Annals of Family Medicine say. In fact, of the 11,110 recruited study subjects between the ages of 52 and 78 who underwent a fecal occult blood test, 46.8 percent failed to have either a repeat test or any other form of follow-up colorectal cancer screening.

Boston Proposes Ban On Sugary Beverages

By ACSH Staff — Sep 21, 2010
The silly season in the fight against obesity is spreading, it seems, from the West coast to the East coast. The latest metropolis to join in the battle against soda is Boston, where city officials are considering a ban on selling sugar-sweetened beverages in government buildings. The anti-soda craze was started by Mayor Gavin Newsom in San Francisco, and now Boston is following suit.

The silly season in the fight against obesity is spreading, it seems, from the West coast to the East coast. The latest metropolis to join in the battle against soda is Boston, where city officials are considering a ban on selling sugar-sweetened beverages in government buildings. The anti-soda craze was started by Mayor Gavin Newsom in San Francisco, and now Boston is following suit.

Get off your posterior, America! Only a few exercise daily

By ACSH Staff — Sep 20, 2010
Only 5 percent of Americans perform vigorous physical activity in any given day, according to a study published last week in the American Journal of Preventive Medicine.

Only 5 percent of Americans perform vigorous physical activity in any given day, according to a study published last week in the American Journal of Preventive Medicine.

Withholding lifesaving drugs to prove a point

By ACSH Staff — Sep 20, 2010
The front page of Sunday’s New York Times featured a heartbreaking story about two cousins, both suffering from widespread melanoma, a lethal type of skin cancer. Both young men’s melanoma had a specific gene mutation called B-RAF, which is specifically targeted by a new drug being tested by Roche Pharmaceuticals.

The front page of Sunday’s New York Times featured a heartbreaking story about two cousins, both suffering from widespread melanoma, a lethal type of skin cancer. Both young men’s melanoma had a specific gene mutation called B-RAF, which is specifically targeted by a new drug being tested by Roche Pharmaceuticals.

IrRASHional Pampers Dry Max Scare

By ACSH Staff — Sep 17, 2010
The Consumer Product Safety Commission announced earlier this month that they could not find a causal relationship between Pampers Dry Max, a thinner absorbent gel material, and diaper rash.

The Consumer Product Safety Commission announced earlier this month that they could not find a causal relationship between Pampers Dry Max, a thinner absorbent gel material, and diaper rash.

Acne Confounds Accutane Depression & Suicide Correlation

By ACSH Staff — Sep 17, 2010
Severe acne is more likely to cause suicide and depression in young people, not the drug Accutane often used to treat it, a new study published in the Journal of Investigative Dermatology finds.

Severe acne is more likely to cause suicide and depression in young people, not the drug Accutane often used to treat it, a new study published in the Journal of Investigative Dermatology finds.